Brain‐derived p‐tau217 may reduce these off‐target effects of Alzheimer's disease pathology, but its performance against neuropathology has not been evaluated.
Abstract
Plasma phosphorylated tau (p‐tau), particularly p‐tau217, is a highly specific biomarker of Alzheimer's disease (AD) pathology. However, plasma p‐tau217 can be elevated in rare non‐AD conditions. Brain‐derived (BD) p‐tau217 may reduce these off‐target effects, but its performance against neuropathology has not been evaluated.
The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...
W. Omori, N. Kajitani, M. Okada-Tsuchioka et al.· Neuropsychopharmacology Repo...· 0 citations
It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...
C. Teunissen, L. Pini, B. Imbimbo· Alzheimer's & Dementia· 0 citations
Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...
Aasim Ali, Muhammad Arif, Usama Ashraf et al.· Brain and Behavior· 0 citations
Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.
Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.